Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03510832
Other study ID # QLEmer201802
Secondary ID
Status Enrolling by invitation
Phase
First received March 20, 2018
Last updated April 26, 2018
Start date March 1, 2018
Est. completion date December 31, 2021

Study information

Verified date March 2018
Source Qilu Hospital of Shandong University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

EAST-STEMI is the first perspective, multicenter, large-scale registry focusing on the evaluation of real-world medical quality (especially PCI quality) and antithrombotic strategies in STEMI patients undergoing emergent PCI in a regional representative sample in China with 2 years follow-up. Clinical decision support tools (including ischemic score, bleeding score, etc) will be developed and validated based on the database. Novel biomarkers to predict the prognosis and to support risk stratification will be explored by using the blood samples.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 8000
Est. completion date December 31, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age>=18yrs

2. STEMI patients undergoing emergent PCI

3. Signed informed consent

Exclusion Criteria:

1. Difficult to follow up or obtain accurate information (e.g., long-term overseas stay, speech or mental disorders)

2. Other severe diseases (e.g., liver failure, renal failure and advanced stage of cancer)

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Qilu Hospital of Shandong University Jinan Shandong

Sponsors (61)

Lead Sponsor Collaborator
Qilu Hospital of Shandong University Affiliated hospital of Taishan medical university, Affiliated Hospital of Weifang Medical University, Anhui Provincial Hospital, Binzhou Medical University Hospital, Central Hospital of Zibo, Chengyang People's Hospital, Dezhou People's Hospital, Dongying People's Hospital, Feicheng People's Hospital, Feixian People's Hospital, Henan Provincial Hospital, Heze Luxin Cardiovascular and Cerebrovascular Hospital, Heze Municipal Hospital, Inner Mongolia People's Hospital, Jinan Central Hospital Affiliated to Shandong University, Jining Integrative Medicine Hospital, Jining Medical University, JINING No.1 People's Hospital, Jinxiang People's Hospital, Laizhou City People's Hospital, Liaocheng People's Hospital, Linyi Central Hospital, Linyi People's Hospital, Linzi District People's Hospital, Longkou People's Hospital, Ningjin County People's Hospital, Peking University Care Luzhong Hospital, Pingdu People's Hospital, Qianfoshan Hospital, Qingdao Center Hospital, Qingdao Hiser Hospital, Qingdao Jiaozhou Central Hospital, Qingdao Municipal Hospital, Qingdao Westcoast New Area Central Hospital, Qingzhou People's Hospital, Shandong Provincial Hospital, Shengli Oilfield Central Hospital, Shouguang people's Hospital, Taian City Central Hospital, Tengzhou Central People's Hospital, The 5th People's Hospital of Jinan, The 6th People's Hospital of Jinan, The Affiliated Hospital of Qingdao University, The First Hospital of Zibo, The Second Hospital of Shandong University, The Second People's Hospital of Liaocheng, The Third Shandong Provincial Hospital, Tianjin Chest Hospital, Weifang People's Hospital, Weifang Traditional Chinese Hospital, Weihai Central Hospital, Weihai Municipal Hospital, Wenshang People's Hospital, Yantai Affiliated Hospital of Binzhou Medical University, Yantai Yuhuangding Hospital, Yantaishan Hospital, Yanzhou Branch of Affiliated Hospital of Jining Medical University, Yidu Central Hospital of Weifang, Yuncheng County People's Hospital, Zhouping People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Net Adverse Clinical Events (NACEs) The primary outcome is the rate of adjudicated NACEs, a composite of major adverse cardiac or cerebral events (MACCEs) and bleeding. MACCEs include cardiac death, reinfarction, urgent revascularization, or stroke. Bleeding is defined by the Bleeding Academic Research Consortium (BARC) definition (types 1-5). BARC type 2 bleeding is considered as minor bleeding, type 3-5 bleeding is considered as major bleeding. 2 years after emergent PCI
Secondary Contrast-induced acute kidney injury (CI-AKI) CI-AKI is defined as an increase in serum creatinine of =0.3mg/dl or =50% from baseline within 72 hours. 72 hours after contrast exposure
Secondary Definite/Probable Stent thrombosis Stent thrombosis is defined according to the Academic Research Consortium criteria. Definite stent thrombosis is defined as angiography or autopsy examination confirmed stent occlusion or thrombus. Probable stent thrombosis is defined as death occurring within 30 days that cannot be attributed to another cause or when myocardial infarction occurs at any time point and is attributable to the target vessel in the absence of angiography confirming another culprit lesion. 2 years after emergent PCI
Secondary Heart failure Heart failure is defined as physician documentation or report of any of the following clinical symptoms of heart failure described as unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention; or the description of rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray. A low ejection fraction alone, without clinical evidence of heart failure does not qualify as heart failure. 2 years after emergent PCI
Secondary Quality of life (QoL) QoL is assessed by using EuroQol-5 Dimension (EQ-5D), which is the most widely used generic instrument to measure QoL. The utility index scores of EQ-5D represent the QoL.The higher the score, the better the QoL. 2 years after emergent PCI
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02871622 - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM N/A
Completed NCT01452139 - Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI) Phase 2/Phase 3
Completed NCT01325116 - Delayed Educational Reminders in Acute Myocardial Infarction (MI) N/A
Completed NCT01625104 - Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI N/A
Completed NCT04023266 - A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI Phase 2
Completed NCT02170103 - Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial N/A
Completed NCT03103620 - Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
Not yet recruiting NCT05975567 - Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
Enrolling by invitation NCT03328156 - Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction N/A
Completed NCT04017169 - No Reflow Phenomenon Incidence and Predictors
Completed NCT03470441 - A Study of Acute Myocardial Infarction Using FDY-5301 Phase 2
Active, not recruiting NCT01433627 - Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX Phase 3
Completed NCT01197742 - Sweetheart-Register: Risk Management of Diabetics With Acute Myocardial Infarction N/A
Terminated NCT03439150 - Resistance STEMI Study N/A
Recruiting NCT03998319 - A Study of Low-dose Intracoronary Thrombolytic Therapy in STEMI (Heart Attack) Patients. Phase 3
Not yet recruiting NCT05974930 - Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction
Active, not recruiting NCT03102723 - Platelet Inhibition to Target Reperfusion Injury Phase 2
Completed NCT03930589 - Remote Ischemic Conditioning in STEMI to Decrease Infarct Size N/A
Not yet recruiting NCT04912167 - The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction Phase 3
Completed NCT02942550 - Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients Phase 4